Anatara Lifesciences Ltd (ASX:ANR) reported cash of $0.471 million at the end of the June 2026 quarter, down from $0.707 million at 31 March, alongside pre-clinical results showing its anti-obesity candidate compound “AOC” produced two independent measures of statistically significant activity in managing weight regain. The company is now reviewing designs for a possible open label clinical trial of the compound
Key Points
- Anatara Lifesciences Ltd (ASX:ANR) filed its 4C cashflow report and Q4 FY26 activities report on 31 July 2026.
- Compound AOC showed a significant reduction in weight regain after cessation of injectable semaglutide (p<0.019) and a significant reduction in perigonadal fat weight (p=0.024).
- Cash at quarter end was $0.471 million, with net operating cash outflows of $0.286 million for the quarter, compared to $0.327 million in the prior quarter.
- Investors may be watching the outcome of the AusIndustry R&D tax incentive claim, lodged 28 July 2026, anticipated to be processed through August.
AOC Compound Shows Statistically Significant Weight-Control Results
The company announced that its research report on the Anti-Obesity Project pre-clinical studies concluded compound AOC demonstrated two independent measures suggesting statistically significant activity in assisting weight reduction management. Compared to a placebo vehicle, AOC showed a significant reduction in weight gain following cessation of injectable semaglutide-induced weight loss, with a p-score below 0.019, and a significant reduction in perigonadal fat weight, with a p-score of 0.024, indicating reduced visceral fat volumes.
Mechanism of Action Studies Remain Inconclusive on GLP-1 Levels
The announcement noted that mechanism of action studies, completed after an unexpected delay in December 2025 due to unavailability of an assay kit, produced a full data set that was inconclusive with respect to showing a direct effect on endogenous GLP-1 levels. The company said it has spent more than $350,000 on the Proof-of-Concept studies for the Anti-Obesity Project and is determining further steps following these outcomes, including evaluation of an open label study design using <a href="https://healthylife7.com/nutrition-moves-to-the-front-line-of-resilient-pig-health/” title=”Nutrition moves to the front line of resilient pig health”>healthy volunteers.
What the $0.471 Million Cash Balance Means for Anatara’s Runway
Anatara’s cash balance fell to $0.471 million at 31 March comparative figure of $0.707 million, with net cash outflows from operating activities of $0.286 million during the quarter, down from $0.327 million in the previous quarter. Aggregate payments to related parties, including directors’ fees and superannuation, totalled $92,000 for the quarter. The company said it continues to maintain prudent financial control over operations while reviewing other opportunities and assets to enhance its project portfolio.
GaRP Project Manuscripts Submitted Amid Continued Commercial Interest
The company reported that manuscripts covering the GaRP project pre-clinical work and the GaRP-IBS clinical trial have been submitted for review and publication, alongside pre-clinical studies using an internationally accepted inflammatory bowel disease mouse model. Anatara said there remains commercial interest in the GaRP project intellectual property. The company also lodged its 2026 AusIndustry registration application for the R&D tax incentive claim on 28 July 2026, anticipated to be processed through August, resulting in a rebate of over $300,000.
